The study involved 143 women (mean age 55.4 ± 13.1 years) treated with neoadjuvant systemic treatment for triple-negative breast cancer between 2015 and 2019.The method to determine ER, PgR, and HER2 negativity was used according to the American Society of Clinical Oncology, College of American Pathologists guidelines: ER and PgR nuclear staining of less than 1% by immunohistochemistry (IHC) and HER2 IHC staining of 0 to 1+ or fluorescent in situ hybridization <2.0 if IHC 2+ or IHC not performed. The gene discussed is PGR; the disease is triple-negative breast carcinoma.